JP2007533625A - 炎症性及び/又は免疫媒介性の骨量減少の予防及び治療 - Google Patents

炎症性及び/又は免疫媒介性の骨量減少の予防及び治療 Download PDF

Info

Publication number
JP2007533625A
JP2007533625A JP2006527336A JP2006527336A JP2007533625A JP 2007533625 A JP2007533625 A JP 2007533625A JP 2006527336 A JP2006527336 A JP 2006527336A JP 2006527336 A JP2006527336 A JP 2006527336A JP 2007533625 A JP2007533625 A JP 2007533625A
Authority
JP
Japan
Prior art keywords
group
alkyl
carboxy
type
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006527336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007533625A5 (cg-RX-API-DMAC7.html
Inventor
ヴィルケンス トーマス
Original Assignee
バイオネットワークス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオネットワークス ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical バイオネットワークス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2007533625A publication Critical patent/JP2007533625A/ja
Publication of JP2007533625A5 publication Critical patent/JP2007533625A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Veneer Processing And Manufacture Of Plywood (AREA)
  • Steroid Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
JP2006527336A 2003-09-22 2004-09-21 炎症性及び/又は免疫媒介性の骨量減少の予防及び治療 Pending JP2007533625A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50471703P 2003-09-22 2003-09-22
US60/504,717 2003-09-22
PCT/EP2004/010582 WO2005027882A1 (en) 2003-09-22 2004-09-21 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss

Publications (2)

Publication Number Publication Date
JP2007533625A true JP2007533625A (ja) 2007-11-22
JP2007533625A5 JP2007533625A5 (cg-RX-API-DMAC7.html) 2008-01-10

Family

ID=34375537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006527336A Pending JP2007533625A (ja) 2003-09-22 2004-09-21 炎症性及び/又は免疫媒介性の骨量減少の予防及び治療

Country Status (15)

Country Link
US (2) US20100087413A1 (cg-RX-API-DMAC7.html)
EP (2) EP2036548A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007533625A (cg-RX-API-DMAC7.html)
AT (1) ATE416761T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004273610B2 (cg-RX-API-DMAC7.html)
CA (1) CA2539741A1 (cg-RX-API-DMAC7.html)
CY (1) CY1111246T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004018338D1 (cg-RX-API-DMAC7.html)
DK (1) DK1663185T3 (cg-RX-API-DMAC7.html)
ES (1) ES2317029T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ546062A (cg-RX-API-DMAC7.html)
PL (1) PL1663185T3 (cg-RX-API-DMAC7.html)
PT (1) PT1663185E (cg-RX-API-DMAC7.html)
SI (1) SI1663185T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005027882A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542595A (ja) * 2006-07-06 2009-12-03 グラクソ グループ リミテッド P2x7受容体アンタゴニストとしての置換n−フェニルメチル−5−オキソ−プロリン−2−アミドおよびそれらの使用方法
WO2010035727A1 (ja) * 2008-09-25 2010-04-01 塩野義製薬株式会社 新規ピロリノン誘導体およびそれを含有する医薬組成物
JP2012041291A (ja) * 2010-08-18 2012-03-01 Institute Of Physical & Chemical Research 歯周病の治療または予防剤
JP2020529449A (ja) * 2017-08-04 2020-10-08 アルデリックス, インコーポレイテッド 高カリウム血症を処置するためのグリチルレチン酸誘導体

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005279845A1 (en) * 2004-08-30 2006-03-09 Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Inhibition of viruses using RNase H inhibitors
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
DE102005026231A1 (de) * 2005-06-07 2006-12-14 Origenis Ag Peptid-Deformylase (PDF) Inhibitoren 3
EP1864668B1 (en) * 2006-06-01 2012-11-21 Novagali Pharma S.A. Use of prodrugs for ocular intravitreous administration
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
KR101022809B1 (ko) * 2008-02-05 2011-03-17 재단법인서울대학교산학협력재단 면역조절에 의한 캔디다알비칸스 기인성 질환의 치료
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
SI2640467T1 (sl) 2010-11-19 2015-04-30 Novartis Ag Kristalinična oblika inhibitorja interakcije MDM2/4 in P53
ITRM20100614A1 (it) * 2010-11-24 2012-05-25 D M G Italia S R L Preparazioni farmaceutiche dell acido 18 beta glicirretico e/o di suoi derivati per infiltrazioni intrarticolari per il trattamento delle artropatie infiammatorie
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
CN105209467B (zh) 2013-05-27 2018-06-08 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
AU2014272695B2 (en) 2013-05-28 2016-10-20 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease
WO2014191911A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
MX2016006667A (es) 2013-11-21 2016-07-26 Novartis Ag Derivados de pirrolo-pirrolona y su uso como inhibidores.
CN104873521A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其应用
CN104873520A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其用途
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
GB201805100D0 (en) * 2018-03-28 2018-05-09 Benevolentai Bio Ltd Treatment of sarcopenic diseases
JP7735185B2 (ja) * 2019-02-07 2025-09-08 アルデリックス, インコーポレイテッド 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体
EP4754084A1 (de) * 2023-07-28 2026-06-10 Symrise AG Heterozyklische verbindungen als physiologische kühlstoffe

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04352795A (ja) * 1991-01-22 1992-12-07 Merck & Co Inc 新規な骨作用剤
JPH07291857A (ja) * 1994-04-27 1995-11-07 Suntory Ltd グリチルレチン酸化合物を有効成分とする骨疾患の予防及び治療剤
WO2002072084A2 (en) * 2001-03-08 2002-09-19 Sterix Limited Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity
JP2003512438A (ja) * 1999-10-28 2003-04-02 バイオネットワークス ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫寛容を誘導するための薬剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3262851A (en) * 1958-06-26 1966-07-26 Biorex Laboratories Ltd Pharmacological compositions containing glycyrrhetinic acid derivative
DE2050072C3 (de) * 1970-10-12 1975-01-30 Inverni Della Beffa S.P.A., Mailand (Italien) Aluminium-tri-3-acetyl-18 betaglycyrrthetinat, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zubereitungen
US3934027A (en) * 1973-05-03 1976-01-20 Pfizer Inc. 18β-Glycyrrhetinic acid amides useful as antiulcer agents
GB2261672A (en) * 1991-11-18 1993-05-26 Michael Braden The use of biomaterials for tissue repair
US20050048007A1 (en) * 2000-11-02 2005-03-03 Inobys Ltd. Plaque reducing composition
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
IL161154A0 (en) 2001-11-22 2004-08-31 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP1461327A1 (en) 2001-11-22 2004-09-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
EP2380899A1 (en) 2002-09-23 2011-10-26 E. I. du Pont de Nemours and Company Isolation and use of ryanodine receptors
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
US20030148349A1 (en) * 2003-01-03 2003-08-07 Shyam Ramakrishnan Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04352795A (ja) * 1991-01-22 1992-12-07 Merck & Co Inc 新規な骨作用剤
JPH07291857A (ja) * 1994-04-27 1995-11-07 Suntory Ltd グリチルレチン酸化合物を有効成分とする骨疾患の予防及び治療剤
JP2003512438A (ja) * 1999-10-28 2003-04-02 バイオネットワークス ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫寛容を誘導するための薬剤
WO2002072084A2 (en) * 2001-03-08 2002-09-19 Sterix Limited Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542595A (ja) * 2006-07-06 2009-12-03 グラクソ グループ リミテッド P2x7受容体アンタゴニストとしての置換n−フェニルメチル−5−オキソ−プロリン−2−アミドおよびそれらの使用方法
WO2010035727A1 (ja) * 2008-09-25 2010-04-01 塩野義製薬株式会社 新規ピロリノン誘導体およびそれを含有する医薬組成物
JP5637562B2 (ja) * 2008-09-25 2014-12-10 塩野義製薬株式会社 新規ピロリノン誘導体およびそれを含有する医薬組成物
JP2012041291A (ja) * 2010-08-18 2012-03-01 Institute Of Physical & Chemical Research 歯周病の治療または予防剤
JP2020529449A (ja) * 2017-08-04 2020-10-08 アルデリックス, インコーポレイテッド 高カリウム血症を処置するためのグリチルレチン酸誘導体
JP7281446B2 (ja) 2017-08-04 2023-05-25 アルデリックス, インコーポレイテッド 高カリウム血症を処置するためのグリチルレチン酸誘導体

Also Published As

Publication number Publication date
EP1663185B1 (en) 2008-12-10
CY1111246T1 (el) 2015-06-11
ES2317029T3 (es) 2009-04-16
WO2005027882A1 (en) 2005-03-31
US20100087413A1 (en) 2010-04-08
CA2539741A1 (en) 2005-03-31
DK1663185T3 (da) 2009-04-06
EP1663185A1 (en) 2006-06-07
PL1663185T3 (pl) 2009-06-30
AU2004273610A1 (en) 2005-03-31
EP2036548A1 (en) 2009-03-18
ATE416761T1 (de) 2008-12-15
SI1663185T1 (sl) 2009-04-30
US20110275584A1 (en) 2011-11-10
NZ546062A (en) 2009-09-25
AU2004273610B2 (en) 2010-07-01
DE602004018338D1 (de) 2009-01-22
PT1663185E (pt) 2009-02-16

Similar Documents

Publication Publication Date Title
AU2004273610B2 (en) Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
TW200820969A (en) Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
KR20100024951A (ko) 세포를 자극하기 위한 방법 및 조성물
KR20010074779A (ko) 치환된 아닐리드 화합물 및 제조방법
JP2003525240A (ja) 糖尿病性腎障害の処置のためのpdgf受容体チロシンキナーゼ阻害剤の使用
MX2010012358A (es) Tratamientos para el mieloma multiple.
CN111253246B (zh) 酰基酸类衍生物及其制备方法和医药用途
CA3149833A1 (en) Regenerating functions and phenotypes of connective tissue through npas2 suppression
US11542290B2 (en) Phenothiazine derivatives and uses thereof
EA019919B1 (ru) Способ подавления роста или метастазирования ангиогенез-зависимой опухоли
Zhang et al. Icariin accelerates fracture healing via activation of the WNT1/β-catenin osteogenic signaling pathway
WO2021197396A1 (zh) 氘代氧化苯砷化合物及其应用
KR102218498B1 (ko) Fxr 작용제들의 조합물
CN109846879B (zh) 亚胺结构类型雄激素受体拮抗剂及其应用
US20070219245A1 (en) Method of use for substituted dipiperidine ccr2 antagonists
WO2024016996A1 (zh) 磷酸萘酚喹在制备治疗自身免疫性疾病药物中的应用
TW201938156A (zh) 二氫吲哚啉酮衍生物
JP2013503908A (ja) ニューロキニン2受容体活性に関連する障害または疾患を治療するための化合物
US20120087980A1 (en) Stimulation of neuroregeneration by flavonoid glycosides
Liu et al. Erythropoietin alleviate obstructive renal fibrosis by regulating immunity and inflammation through miR-21-5p/SPRY1/ERK1/2/NF-κB pathway inhibition
CN105853420A (zh) 苯扎托品及其药学上可接受的盐的新应用
US20250177422A1 (en) Co-administration of a co-crystal of psilocybin and psilocin with an atypical antipsychotic
JP7268264B2 (ja) ピロロピリミジン化合物を有効成分とする炎症性疾患の予防及び/又は治療剤
US20160152566A1 (en) Tricyclic pyrrole compounds, their preparation and use in medicaments
CN119033764A (zh) 白杨素增敏vs4718或普纳替尼在治疗食管鳞癌中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070921

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101019

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101026

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101228

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111125